Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Angiogenesis research: Guidelines for translation to clinical application
Autore:
Folkman, J; Browder, T; Palmblad, J;
Indirizzi:
Childrens Hosp, Boston, MA 02115 USA Childrens Hosp Boston MA USA 02115Childrens Hosp, Boston, MA 02115 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA Huddinge Univ Hosp, Stockholm, Sweden Huddinge Univ Hosp Stockholm Sweden ddinge Univ Hosp, Stockholm, Sweden Karolinska Inst, Stockholm, Sweden Karolinska Inst Stockholm SwedenKarolinska Inst, Stockholm, Sweden
Titolo Testata:
THROMBOSIS AND HAEMOSTASIS
fascicolo: 1, volume: 86, anno: 2001,
pagine: 23 - 33
SICI:
0340-6245(200107)86:1<23:ARGFTT>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW ANGIOGENESIS; HUMAN MULTIPLE-MYELOMA; METASTATIC BREAST-CANCER; FIBROBLAST GROWTH-FACTOR; TUMOR ANGIOGENESIS; ORAL ETOPOSIDE; ANTIANGIOGENIC ACTIVITY; ENDOGENOUS INHIBITOR; DRUG-RESISTANCE;
Keywords:
angiogenesis; leukemia; antiangiogenic therapy; angiogenesis inhibitor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
101
Recensione:
Indirizzi per estratti:
Indirizzo: Folkman, J Childrens Hosp, Hunnewell 103,300 Longwood Ave, Boston, MA 02115 USA Childrens Hosp Hunnewell 103,300 Longwood Ave Boston MA USA 02115
Citazione:
J. Folkman et al., "Angiogenesis research: Guidelines for translation to clinical application", THROMB HAEM, 86(1), 2001, pp. 23-33

Abstract

Angiogenesis research is being translated to the clinic. Certain guidelines may facilitate this effort. Recruitment of endothelial cells by a tumor is an early event in angiogenesis, a process regulated at genetic and epigenetic levels. The microvascular endothelial cell has become an important second target in cancer therapy. Angiogenesis inhibitors are either "direct" or "indirect" and their optimal dosing depends on a different logic than conventional chemotherapy. Conversely, antiangiogenic scheduling of chemotherapy can by-pass drug resistance. Like all solid tumors, hematologic malignancies are angiogenesis-dependent. Further, angiogenesis is modulated by proteins and cells from the hematopoietic and hemostatic systems. Clinical testing of angiogenesis inhibitors has accentuated the need for surrogate markers of tumor angiogenesis activity. Microvessel density, so valuable as a prognostic indicator of metastatic risk, cannot determine efficacy of an angiogenesis inhibitor. In the future, angiogenesis inhibitors may be added to chemotherapy or to radiotherapy, or to other modalities. Also, combinationsof angiogenesis inhibitors may be administered together.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 13:42:30